Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Elizabeth Bhatt also recently made the following trade(s):

• On Wednesday, February 18th, Elizabeth Bhatt sold 4,000 shares of Septerna stock. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00.

Septerna Trading Up 4.6%

Septerna stock traded up $1.14 during mid-day trading on Friday, hitting $26.13. The stock had a trading volume of 390,347 shares, compared to its average volume of 303,779. The firm has a market capitalization of $1.17 billion, a P/E ratio of -23.54 and a beta of 3.50. The firm’s 50 day moving average is $26.18 and its 200 day moving average is $25.03. Septerna, Inc. has a one year low of $5.73 and a one year high of $32.63.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. As a group, equities research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SEPN. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. JPMorgan Chase & Co. lifted their price target on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Finally, Wells Fargo & Company increased their price objective on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SEPN. Group One Trading LLC boosted its holdings in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of Septerna during the 4th quarter valued at about $35,000. Russell Investments Group Ltd. bought a new position in shares of Septerna during the 3rd quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna during the 4th quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Septerna during the 4th quarter valued at about $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.